Cargando…
Prospective approaches to enhancing CAR T cell therapy for glioblastoma
Glioblastoma (GBM) is the most common malignant brain tumor. The poor clinical outcome and overall ineffectiveness of current standard treatments, including surgery, chemotherapy, and radiation, highlight the urgent need for alternative tumor-specific therapies for GBM. Chimeric antigen receptor (CA...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582117/ https://www.ncbi.nlm.nih.gov/pubmed/36275671 http://dx.doi.org/10.3389/fimmu.2022.1008751 |
_version_ | 1784812763063779328 |
---|---|
author | Choi, Sun Il Yin, Jinlong |
author_facet | Choi, Sun Il Yin, Jinlong |
author_sort | Choi, Sun Il |
collection | PubMed |
description | Glioblastoma (GBM) is the most common malignant brain tumor. The poor clinical outcome and overall ineffectiveness of current standard treatments, including surgery, chemotherapy, and radiation, highlight the urgent need for alternative tumor-specific therapies for GBM. Chimeric antigen receptor (CAR) T cell therapy is a revolutionary therapeutic strategy for hematological malignancies, but the optimal potency of CAR T cell therapy for solid tumors, especially GBM, has not been achieved. Although CAR T cell therapeutic strategies for GBM have been assessed in clinical trials, the current antitumor activity of CAR T cells remains insufficient. In this review, we present our perspective on genetically modifying CAR constructs, overcoming T cell dysfunctions, and developing additional treatments that can improve CAR T cell effectiveness, such as functionality, persistence, and infiltration into tumor sites. Effectively improved CAR T cells may offer patients with GBM new treatment opportunities, and this review is intended to provide a comprehensive overview for researchers to develop potent CAR T cells using genetic engineering or combinatorial preparations. |
format | Online Article Text |
id | pubmed-9582117 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95821172022-10-21 Prospective approaches to enhancing CAR T cell therapy for glioblastoma Choi, Sun Il Yin, Jinlong Front Immunol Immunology Glioblastoma (GBM) is the most common malignant brain tumor. The poor clinical outcome and overall ineffectiveness of current standard treatments, including surgery, chemotherapy, and radiation, highlight the urgent need for alternative tumor-specific therapies for GBM. Chimeric antigen receptor (CAR) T cell therapy is a revolutionary therapeutic strategy for hematological malignancies, but the optimal potency of CAR T cell therapy for solid tumors, especially GBM, has not been achieved. Although CAR T cell therapeutic strategies for GBM have been assessed in clinical trials, the current antitumor activity of CAR T cells remains insufficient. In this review, we present our perspective on genetically modifying CAR constructs, overcoming T cell dysfunctions, and developing additional treatments that can improve CAR T cell effectiveness, such as functionality, persistence, and infiltration into tumor sites. Effectively improved CAR T cells may offer patients with GBM new treatment opportunities, and this review is intended to provide a comprehensive overview for researchers to develop potent CAR T cells using genetic engineering or combinatorial preparations. Frontiers Media S.A. 2022-10-06 /pmc/articles/PMC9582117/ /pubmed/36275671 http://dx.doi.org/10.3389/fimmu.2022.1008751 Text en Copyright © 2022 Choi and Yin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Choi, Sun Il Yin, Jinlong Prospective approaches to enhancing CAR T cell therapy for glioblastoma |
title | Prospective approaches to enhancing CAR T cell therapy for glioblastoma |
title_full | Prospective approaches to enhancing CAR T cell therapy for glioblastoma |
title_fullStr | Prospective approaches to enhancing CAR T cell therapy for glioblastoma |
title_full_unstemmed | Prospective approaches to enhancing CAR T cell therapy for glioblastoma |
title_short | Prospective approaches to enhancing CAR T cell therapy for glioblastoma |
title_sort | prospective approaches to enhancing car t cell therapy for glioblastoma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582117/ https://www.ncbi.nlm.nih.gov/pubmed/36275671 http://dx.doi.org/10.3389/fimmu.2022.1008751 |
work_keys_str_mv | AT choisunil prospectiveapproachestoenhancingcartcelltherapyforglioblastoma AT yinjinlong prospectiveapproachestoenhancingcartcelltherapyforglioblastoma |